scholarly journals Urinary Incontinence during Sleep Associated with Extended Release Form of Bupropion HCI

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Filiz Izci ◽  
Merve Iris Koc ◽  
Rabia Bilici ◽  
Murat Yalcin ◽  
Engin Emrem Bestepe
Keyword(s):  
Urinary Incontinence ◽  
Side Effect ◽  
Extended Release ◽  
Immediate Release ◽  
Dosage Forms ◽  
Side Effect Profile ◽  
Dopamine Reuptake ◽  
Safe Side ◽  
Dopamine Reuptake Inhibitor ◽  
Release Form

Bupropion hydrochloride (HCI) is an antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor and has three different dosage forms including immediate release (IR), sustained release (SR), and extended release (ER). Despite its relatively safe side effect profile bupropion may cause several side effects. Here, we aimed to report a case with major depression using extended release form of bupropion hydrochloride who was presented with urinary incontinence during sleep, an uncommon side effect of bupropion.

High Familial Correlation in Methylphenidate Response and Side Effect Profile

2015 ◽  
Vol 23 (2) ◽  
pp. 135-139 ◽  
Author(s):  
Michal Gazer-Snitovsky ◽  
Ayelet Brand-Gothelf ◽  
Gal Dubnov-Raz ◽  
Abraham Weizman ◽  
Doron Gothelf
Keyword(s):  
Side Effect ◽  
Rating Scale ◽  
Immediate Release ◽  
Familial Correlation ◽  
Side Effect Profile ◽  
Emotional Symptoms ◽  
Clinical Global Impression Scale ◽  
Intraclass Correlations ◽  
History Of ◽  
Loss Of Appetite

Objective: To examine whether a familial tendency exists in clinical response to methylphenidate. Method: Nineteen pairs of siblings or parent–child stimulant-naive individuals with ADHD were prescribed methylphenidate–immediate release, and were comprehensively evaluated at baseline, Week 2, and Week 4, using the ADHD Rating Scale IV, Clinical Global Impression Scale, and the Barkley Side Effects Rating Scale. Results: We found significant intraclass correlations in family member response to methylphenidate–immediate release and side effect profile, including emotional symptoms and loss of appetite and weight. Conclusion: Family history of response to methylphenidate should be taken into account when treating ADHD.

scholarly journals Pramipexole and its Extended Release Formulation for Parkinson's Disease

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S5210 ◽  
Author(s):  
Paul S. Fishman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Immediate Release ◽  
Motor Fluctuations ◽  
Release Formulation ◽  
Extended Release Formulation ◽  
Release Preparation ◽  
Early Parkinson’S Disease ◽  
Release Form

Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with the enhanced patient compliance seen with once a day dosing, there are other potential advantages of extended release preparations of dopamine agonists. Patients initiated on pramipexole have a lower incidence of developing motor fluctuations including dyskinesia than those initiated on L-DOPA. Pramipexole requires a prolonged dose titration compared to L-DOPA, and generally does not have the efficacy of L-DOPA. The extended release form of pramipexole shows comparable mean and peak serum levels with once a day dosing as seen with three times a day dosing of the immediate release preparation. The extended release preparation has been studied in randomized multicenter clinical trial against both placebo and the immediate release preparation in the setting of early Parkinson's disease as monotherapy and in more advanced patients with motor fluctuations on L-DOPA. In both settings the extended release preparation was superior to placebo and comparable to the immediate release form in efficacy with a similar side effect profile including nausea, sleepiness, leg edema, dyskinesias, hallucinations and impulse control disorders.

New onset multimodal hallucinations associated with mirtazapine: a case report

2010 ◽  
Vol 22 (5) ◽  
pp. 837-839 ◽  
Author(s):  
Kalpana P. Padala ◽  
Prasad R. Padala ◽  
Timothy Malloy ◽  
William J. Burke
Keyword(s):  
Weight Loss ◽  
Case Report ◽  
Side Effect ◽  
The Elderly ◽  
Side Effect Profile ◽  
Visual Hallucinations ◽  
Care Needs ◽  
Treatment Of Depression ◽  
Safe Side ◽  
New Onset

ABSTRACTMirtazapine, a commonly used antidepressant, has a relatively safe side effect profile and is commonly used in the elderly for treatment of depression. It has been proposed as being particularly suitable for patients with depression associated with insomnia and weight loss. Although mental status changes and perceptual abnormalities secondary to its use are rare, special care needs to be taken, especially while starting treatment or while increasing the dose. We report three cases of auditory, musical and visual hallucinations associated with the use of mirtazapine.

Sign in / Sign up

Export Citation Format

Share Document